Cyclooxygenase-2 inhibitors: Promise or peril?

Mediators of Inflammation

Volumn 11, Issue 5, 2002, Pages 275-286

  Mengle Gaw, Laurel J ^a   Schwartz, Benjamin D ^a  

^a Camden Group   (United States)

Author keywords

Cardioprotection; COX 2 specific inhibitor; Gastrointestinal toxicity; Nonsteriodal anti inflammatory drugs (NSAIDs); Prostaglandins; Rheumatoid arthritis

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; ANTIDIABETIC AGENT; ANTIINFLAMMATORY AGENT; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETODOLAC; ETORICOXIB; FLURBIPROFEN; IBUPROFEN; INDOMETACIN; KETOPROFEN; KETOROLAC; MEFENAMIC ACID; MELOXICAM; NABUMETONE; NAPROXEN; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OXAPROZIN; PHENYLBUTAZONE; PIROXICAM; ROFECOXIB; SULINDAC; TOLMETIN; UNINDEXED DRUG; VALDECOXIB; ISOENZYME; MEMBRANE PROTEIN; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; PTGS1 PROTEIN, HUMAN; PTGS2 PROTEIN, HUMAN;

ACUTE KIDNEY FAILURE; ASEPTIC MENINGITIS; BODY WEIGHT DISORDER; BRAIN HEMORRHAGE; CONGESTIVE HEART FAILURE; DIGESTIVE SYSTEM PERFORATION; DIGESTIVE SYSTEM ULCER; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG SPECIFICITY; EDEMA; ENZYME INHIBITION; EOSINOPHILIA; FETAL HEMORRHAGE; FEVER; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; GRANULOMATOUS HEPATITIS; HEADACHE; HEARING LOSS; HUMAN; INTESTINE OBSTRUCTION; INTRAHEPATIC CHOLESTASIS; LIVER DYSFUNCTION; LIVER TOXICITY; NEONATAL HEMORRHAGE; NEPHROTOXICITY; NEUROTOXICITY; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; RASH; REVIEW; RISK BENEFIT ANALYSIS; STOMACH OBSTRUCTION; THROMBOEMBOLISM; TINNITUS; DRUG ANTAGONISM; INFLAMMATION; METABOLISM;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; HUMANS; INFLAMMATION; ISOENZYMES; MEMBRANE PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES;

EID: 0036809604     PISSN: 09629351     EISSN: None     Source Type: Journal    
DOI: 10.1080/09629350290000041     Document Type: Review

References (101)

1. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971; 231: 232-235.
2. 2 synthase (cyclooxygenase) in human monocytes. J Biol Chem 1990; 265: 16737-16740.
3. Masferrer JL, Zweifel BS, Seibert K, Needleman P. Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice. J Clin Invest 1990; 86: 1375-1379.
4. Xie W, Robertson DL, Simmons DL. Mitogen-inducible prostaglandin G/H synthase: A new target for nonsteroidal anti-inflammatory durgs. Drug Dev Res 1992; 25: 249-265.
5. 2 synthase-1. Nature 1994; 367: 243-249.
6. 2 synthase. Nat Struct Biol 1995; 2: 637-643.
7. Luong C, Miller A, Barnett J, Chow J, Ramesha C, Browner MF. Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2. Nat Struct Biol 1996; 3: 927-933.
8. Gierse JK, Hauser SD, Creely DP, Koboldt C, Rangwala SH, Isakson PC, Seibert K. Expression and selective inhibition of the constitutive and inducible forms of human cyclooxygenase. Biochem J 1995; 305: 479-484.
9. Chan C-C, Boyce S, Brideau C, Charleson S, Cromlish W, Ethier C, et al. Rofecoxib [Vioxx, MK-0966; 4-(4′-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: A potent and orally active cylooxygenase-2 inhibitor. Pharmacological and biochemical profiles. J Pharm Exp Ther 1999; 290: 551-560.
10. Gierse JK, Koboldt CM, Walker MC, Seibert K, Isakson PC. Kinetic basis for selective inhibition of cyclo-oxygenases. Biochem J 1999; 339: 607-614.
11. Komhoff M, Grone HJ, Klein T, Seyberth HW, Nusing RM. Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney: Implication for renal function. Am J Physiol 1997; 272: 460-468.
12. DeWitt D, Smith WL. Yes, but do they still get headaches? Cell 1995; 83: 345-348.
13. Halushka PV. Prostaglandins and related compounds. In: Goldman L, Bennett JC, eds. Cecil Textbook of Medicine, 21st Edn. Philadelphia, PA: W.B. Saunders Company, 2000; 1189-1194.
14. Brune K, Graft P. Non-steroid anti-inflammatory drugs: Influence of extracellular pH on biodistribution and pharmacological effects. Biochem Pharmacol 1978; 27: 525-530.
15. Brideau C, Kargman S, Liu S, Dallob AL, Ehrich EW, Rodger IW, Chan C-C. A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors. Inflamm Res 1996; 45: 68-74.
16. Masferrer JL, Zweibel BS, Manning PT, Hauser SD, Leahy KM, Smith WG, Isakson, PC, Seibert K. Selective inhibition of inducible cyclooxygenase 2 in vivo is anti-inflammatory and nonulcerogenic. Proc Natl Acad Sci USA 1994; 91: 3228-3232.
17. Masferrer JL, Isakson PC, Seibert K. Cylcooxygenase-2 inhibitors. A new class of anti-inflammatory agents that spare the gastrointestinal tract. Gastroenterol Clin North Am 1996; 25: 363-372.
18. Schwartz BD. COX-2 inhibitors: A safer class of drugs for inflammatory pain. Novel targets in the treatment of pain. International Business Communications Compendium. Southborough, MASS, 1997.
19. Feldman M, McMahon AT. Do cyclooxygenase-2 inhibitors provide benefits similar to those of traditional nonsteroidal anti-inflammatory drugs, with less gastrointestinal toxicity? Ann Int Med 2000; 132: 134-143.
20. Riendeau D, Percival MD, Brideau C, Charleson S, Dube D, Ethier D, et al. Etoricoxib (MK-0663): Preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J Pharmacol Exp Ther 2001; 296: 558-566.
21. Dray A, Urban L. New pharmacological strategies for pain relief. Ann Rev Pharmacol Toxicol 1996; 36: 253-280.
22. Yamamoto T, Nozaki-Taguchi N. Analysis of the effects of cyclooxygenase (COX-1 and COX-2) in spinal nociceptive transmission using indomethacin, a non-selective COX inhibitor, and NS-398, a COX2-selecitve inhibitor. Brain Res 1996; 739: 104-110.
23. Cashman JN. The mechanism of action of NSAIDs in analgesia. Drugs 1996; 52: 13-23.
24. Willingale HL, Gardiner NJ, McLymont N, Giblett S, Grubb B. Prostanoids synthesized by cyclooxygenase isoforms in rat spinal cord and their contribution to the development of neuronal hyper-excitability. Br J Pharmacol 1997; 122: 1593-1604.
25. Smith CJ, Zhang Y, Koboldt CM, et al. Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc Natl Acad Sci USA 1988; 95: 13313-13318.
26. Seibert K, Zhang Y, Leahy K, Hauser S, Masferrer J, Perkins W, Lee L, Isakson P. Pharmacological and biomedical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci USA 1994; 91: 12013-12017.
27. Beiche F, Scheuerer S, Brune K, Geisslinger G, Goppeh-Struebe M. Up-regulation of cyclooxygenase-2 mRNA in the rat spinal cord following peripheral inflammation. FEBS Lett 1996; 390: 165-169.
28. Lane NE. Pain management in osteoarthritis: The role of COX-2 inhibitors. J Rheum 1997; 24: 20-24.
29. Morrison BW, Daniels SE, Kotey P, Cantu N, Seidenberg B. Rofecoxib, a specific cyclooxygenase-2 inhibitor, in primary dysmenorrhea: A randomized controlled trial. Obstet Gynecol 1999; 94: 504-508.
30. Coceani F, Lees J, Bishai I. Further evidence implicating prostaglandin E2 in the genesis of pyrogen fever. Am J Physiol 1988; 254: R463-R469.
31. Cao C, Matsumura K, Yamagata K, Watanabe Y. Induction by lipopolysaccharide of cyclooxygenase-2 mRNA in rat brain: Its possible role in the febrile response. Brain Res 1995; 697: 187-196.
32. Li S, Wang Y, Matsumura K, Ballou LR, Morhan SG, Blatteis CM. The febrile reponse to lipopolysaccharide is blocked in cyclooxygenase-2 (-/-) but not cyclooxygenase-1 (-/-) mice. Brain Res 1996; 825: 86-94.
33. Schwartz JI, Chan CC, Mukhopadhyay S, McBride KJ, Jones TM, Adcock S, et al. Cyclooxygenase-2 inhibition by rofecoxib reverses naturally occurring fever in humans. Clin Pharmacol Ther 1999; 65: 653-660.
34. Prescribing information for Celebrex® (celecoxib). Physician's Desk Reference, 56th Edn. Montvale, New Jersey. Medical Economics Co., 2002.
35. Prescribing information for Vioxx® (rofecoxib). Physician's Desk Reference, 56th Edn. Montvale, New Jersey. Medical Economics Co., 2002.
36. Anderson GD, Hauser SD, McGarity KL, Bremer ME, Isakson PC Gregory SA. Selective inhibition of cyclooxygenase (COX)-2 reverses inflammation and expression of COX-2 and interleukin 6 in rat adjuvant arthritis. J Clin Invest 1996; 97: 2672-2679.
37. Amin AR, Attur M, Patel RN, Thakker GS, Marshall PJ, Rediske J, Stuchin SA, Patel IR, Abramson SB. Superinduction of cyclooxygenase-2 in human osteoarthritis-affected cartilage: Influence of nitric oxide. J Clin Invest 1997; 99: 1231-1237.
38. Kang RY, Freire-Moar J, Sigal E, Chu CQ. Expression of cyclooxygenase-2 in human and an animal model of rheumatoid arthritis. Br J Rheum 1996; 35: 711-718.
39. Crofford LJ. COX-1 and COX-2 tissue expression: Implications and predictions. J Rheum 1997; 24: 15-19.
40. Hubbard R, Geis GS, Woods E, Yu S, Zhao W. Efficacy, tolerability, and safety of celecoxib, a specific COX-2 inhibitor, in osteoathritis. Arthritis Rheum 1998; 41 (Suppl 9): S196.
41. Saag K, Fisher C, McKay J, et al., for the MK-0966 Phase III Protocol 033 Study Group. MK-0966, a specific COX-2 inhibitor, has clinical efficacy comparable to ibuprofen in the treatment of knee and hip osteoarthritis in a 6-week controlled clinical trial. Arthritis Rheum 1998; 41 (Suppl 9): S196.
42. Smalley WE, DuBois RN. Colorectal cancer and nonsteroidal anti-inflammatory drugs. Adv Pharmacol 1997; 39: 1-19.
43. Kune GA, Kune S, Watson LF. Colorectal cancer risk, chronic illnesses, operations, and medications: Case control results from the Melbourne Colorectal Cancer Study. Cancer Res 1988; 48: 4399-4404.
44. Thun MJ, Namboodri MM, Heath CW Jr. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991; 325: 1593-1596.
45. Waddell WR, Ganser GF, Cerise EJ, Loughry RW. Sulindac for polyposis of the colon. Am J Surg 1989; 157: 175-179.
46. Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E, Trzaskos JM, Evans JF, Taketo MM. Suppression of intestinal polyposis in Apc#s716Δ knockout mice by inhibition of cyclooxygenase-2 (COX-2). Cell 1996; 87: 803-809.
47. Kawamori T, Rao CV, Seibert K, Reddy BS. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res 1998; 58: 409-412.
48. Eberhart CE, Coffrey RJ, Radhika A, Giardiello FM, Ferrenbach S, Dubois RN. Up-regulation of cyclooxygenase-2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994; 107: 1183-1188.
49. Food and Drug Administration. Food and Drug Administration Oncologic Drugs Advisory Committee Meeting on Celecoxib Proceedings, 14 December 1999. UD Dept of Health and Human Services, Rockville Maryland.
50. Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LB, Lipsky P. Cyclooxygenase in biology and disease. FASEB J 1998; 12: 1063-1073.
51. Thun MJ, Namboodiri MM, Heath CW Jr. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991; 325: 1593-1596.
52. Zhang F, Subbaramaiah K, Altorki N, Dannenberg AJ. Dihydroxy bile acids activate the transcription of cyclooxygenase-2. J Biol Chem 1998; 273: 2424-2428.
53. Rich JB, Rasmussen DX, Folstein MF, Carson KA, Kawas C, Brandt J. Nonsteroidal anti-inflammatory drugs in Alzheimer's disease. Neurology 1995; 45: 51-55.
54. Rogers J, Kirby LC, Hempelman SR, Berry DL, McGeer PL, Kaszniak AW, Zalinski J, Colfield M, Mansukhani L, Willson P, et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology 1993; 43: 1609-1611.
55. in't Veld BA, Ruitenberg A, Hofman A, Launer, LJ, van Duijn CM, Stijnen T, et al. Nonsteroidal anti-inflammatory durgs and the risk of Alzheimer's disease. N Engl J Med 2001; 345: 1515-1521.
56. Breitner JCS, Gau BA, Welsh KA, Plassmna BL, McDonald WM, Helms MJ, Anthony JC. Inverse association of anti-inflammatory treatments and Alzheimer's disease; initial results of a co-twin control study. Neurology 1994; 44: 227-232.
57. Stewart WF, Kawas C, Corrada M, Metrer J. Risk of Alzheimer's disease and NSAID use. Neurology 1997; 48: 626-632.
58. Yamagata K, Andreasson KI, Kaufman WE, Barnes CA, Worley PF. Expression of a mitogen-inducible cyclooxygenase in brain neurons: Regulation by synaptic activity, and glucocorticoids. Neuron 1993; 1192: 371-386.
59. Kaufman WE, Worley PF, Pegg J, Bremer M, Isakson P. COX-2, a synaptically-induced enzyme, is expressed by excitatory neurons at postsynaptic sites in rat cerebral cortex. Proc Natl Acad Sci USA 1996; 93: 2317-2321.
60. Bauer MKA, Lieb K, Schulze-Osthuff K, Berger M, Gebicke-Haerter PJ, Bauer J, Fiebich BL. Expression and regulation of cyclooxygenase-2 in rat microglia. Eur J Biochem 1997; 243: 726-731.
61. Schlegel SI. General characteristics of nonsteroidal anti-inflammatory drugs. In Paulus HE, Furst DE, Dromgoole S, eds. Drugs for Rheumatic Disease. New York: Churchill Livingston, 1987; 203-226.
62. Redfern JS, Feldman M. Role of endogenous prostaglandins in preventing gastrointestinal ulceration: Induction of ulcers by antibodies to prostaglandins. Gastroenterology 1989; 96 (Suppl): 596-605.
63. Schoen RT, Vender RJ. Mechanisms of non-steroidal anti-inflammatory drug-induced gastric damage. Am J Med 1989; 86: 449-458.
64. Schattenkirchner M. An updated safety profile of etodolac in several thousand patients. Eur J Rheumatol Inflamm 1990; 10: 56-65.
65. Distel M, Mueller C, Bluhmki E, Fries J. Safety of meloxicam: A global analysis of clinical trials. Br J Rheumatol 1996; 35 (Suppl 1): 68-77.
66. Lanza FL, Rack MF, Callison DA, et al. A pilot endoscopic study of the gastroduodenal effects of SC-58635, a novel COX-2-selective inhibitor. Gastroenterology 1997; 112 (Suppl): A194.
67. Lanza F, Simon T, Quan H, et al. Selective inhibition of cyclooxygenase-2 (COX-2) with MK-0966 (250 mg Q.D.) is associated with less gastroduodenal damage than aspirin (ASA) 650 mg Q.D. or ibuprofen (IBU) 800 mg T.I.D. Gastroenterology 1997; 112 (Suppl): A194.
68. McCarthy DM. Non-steroidal anti-inflammatory drug-related gastrointestinal toxicity: Definitions and epidemiology. Am J Med 1998; 105 (Suppl 5A): 35-95.
69. Silverstein FE, Faich G, Goldstein JL et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis, and rheumatoid arthritis. The CLASS study: A randomized clinical trial. JAMA 2000; 284: 1247-1255.
70. Arthritis Advisory Committee Meeting, 7 February 2001 for NDA 20-998/S009 Celebrex (celecoxib) [http://www.fda.gov/ohrms/dock-ets/ac/01/briefing/3677b1.htm].
71. Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001; 345: 1809-1817.
72. Bomkbardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343: 1520-1528
73. Cronberg S, Wallmar E, Soderberg I. Effect on platelet aggregation of oral administration of 10 non-steroidal analgesics to humans. Scand J Haematol 1984; 33: 155-159.
74. Clements PJ, Paulus HE. Non-steroidal antirheumatic drugs. In Kelley WN, et al., eds. Textbook of Rheumatology, 5th Edn. Philadelphia, PA: WB Saunders, 1997; 707-740.
75. Mengle-Gaw L, Hubbard RC, Karim A, Yu S, Talwalker S, Isakson P, Geis SG, Schwartz BD. A study of the platelet effects of SC-58635, a novel COX-2 selective inhibitor. Arthritis Rheum 1997; 40 (Suppl 9): S93.
76. Kroll MH, Hellums JD, McIntire LV, Schafer AI, Moake JL. Platelets and shear stress. Blood 1996; 88: 1525-1541.
77. Schafer AI. Effects of nonsteroidal anti-inflammatory therapy on platelets. Am J Med 1999; 106 (5B): 25S-36S.
78. del Rincón I, Williams K, Stern PM, Freeman GL, Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001; 44: 2737-2745.
79. Watson DJ, Rhodes T. Higher incidence of thromboembolic events among patients with rheumatoid arthritis vs. osteoarthritis, and vs. no arthritis, in the general practice research database (GPRD) [EULAR abstract # OP0109]. Presented at the European Congress of Rheumatology, Prague, Czech Republic, 13-16 June 2001 [http://www.eular-.org/eular2001/AbstractsOnline.cfm].
80. White WB, Faich G, Whelton A, Maurath, C, Ridge NJ, Verburg KM, et al. Comparison of thrombolic events in patients treated with Celecoxib, a cyclooxygnease-2 specific inhibitor, versus ibuprofen or diclofenac. Am J Cardiol 2002; 89: 425-430
81. Henry D, Page J, Whyte I, Nanra R, Hall C. Consumption of nonsteroidal anti-inflammatory drugs and the development of functional renal impairment in elderly subjects: Results of a case-control study. Br J Clin Pharmacol 1997; 44: 85-90.
82. Fored CM, Ejerblad E, Lindblad P, Fryzek JP, Dickman PW, Signorello LB, et al. Acetaminophen, aspirin, and chronic renal failure. N Engl J Med 2001; 345: 1801-1808
83. Cheng HF, Wang JL, Zhang MZ, Miyazaki Y, Ichikawa I, McKanna JA, Harris RC. Angiotensin II attenuates renal cortical cyclooxygenase-2 expression. J Clin Invest 1999; 103: 653-961.
84. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, Fitzgerald GA. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA 1999; 96: 272-277.
85. Prescribing information for NSAIDs, Physician's Desk Reference, 56th Edn. Montvale, New Jersey, Medical Economics Co., 2002.
86. Zhao SZ, Reynolds MW, Lefkowith J, Whelton A, Arellano FM. A comparison of renal-related adverse drug reactions between rofecoxib and celecoxib, based on the World Health Organization/Uppsala Monitoring Centre safety database. Clin Ther 2001; 23: 1478-1491.
87. Katz LM, Love PY. NSAIDs and the liver. In: Famaey JP, Paulus HE, eds. Clinical Applications of NSAIDs: Subpopulation Therapy and New Formulations. NewYork: Marcel Dekker, 1992; 247-263.
88. Garcia Rodriguez LA, Williams R, Debry LE, et al. Acute liver injury associated with nonsteroidal anti-inflammatory drugs and the role of risk factors. Arch Intern Med 1994; 154: 311-315.
89. Rashad S, Revell P, Hemingway A, Low F, Rainsford K, Walker FS. Effect of nonsterdidal anti-inflammatory drugs on the course of osteoarthritis. Lancet 1989; 2: 519-522.
90. Jones AC, Doherty M. The treatment of osteoarthritis. Br J Clin Pharmacol 1992; 33: 357-363.
91. Rainsford KD, Ying C, Smith FC. Effects of meloxicam, compared with other NSAIDs, on cartilage proteoglycan metabolism, synovial prostaglandin E2, and production of interleukins 1, 6, and 8 in human and porcine explants in organ culture. J Pharm Pharmacol 1997; 49: 991-998.
92. Kawaguchi H, Pilbeam CC, Harrison JR, Raisz LG. The role of prostaglandins in the regulation of bone metabolism. Clin Orthop Relat Res 1995; 313: 36-46.
93. Woodiel FN, Fall PM, Raisz LG. Anabolic effects of prostaglandins in cultured fetal rat calvariae: Structure-activity relations and sugnal tranduction pathway. J Bone Miner Res 1996; 11: 1249-1255.
94. Ho ML, Chang JK, Chuang LY, Hsu HK, Wang GJ. Effects of nonsteroidal anti-inflammatory drugs and prostaglandins on osteoblastic function. Biochem Pharmacol 1999; 58: 983-990.
95. Jeffcoat MK, Reddy MS, Moreland LW, Koopman WJ. Effects of nonsteroidal anti-inflammatory drugs on bone loss in chronic inflammatory disease. Ann NY Acad Sci 1993; 696: 292-302.
96. Jiang Y, Zhao J, Genant HK, Dequeker J, Geusens P. Bone mineral density and biomechanical properties of spine and femur in ovarectomized rats treated with naproxen. Bone 1998; 22: 509-514.
97. Saino H, Matsuyama T, Takada J, Kaku T, Ishi S. Long-term treatment with indomethacin reduces vertebral bone mass and strength. J Bone Miner Res 1997; 12: 1844-1850.
98. Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van de Putte LBA, Lipsky PE. Cyclooxygenase in biology and disease. FASEB J 1998; 12: 1063-1070.
99. Mastbergen SC, Bijlsma JWJ, Lafeber FPJG. Selective COX-2 inhibition is beneficial for matrix turnover in osteoarthritic cartilage: A human in vitro study. Arthritis Rheum 2001; 44 (Suppl): S307.
100. Yaron I, Shirazi I, Judovich R, Yaron M. Effects of rofecoxib on metalloproteinases and nitric oxide production by human osteoarthritic synovial tissue and cartilage cultures. Arthritis Rheum 2001; 44 (Suppl): S308.
101. Genovese MC, Ma T, Ikenoue T, Matsurra I, Trindale M, Wong N, et al. COX-2 selective NSAID decreases bone ingrowth in vivo. Arthritis Rheum 2001; 44 (Suppl): S232.